"What public company could buy another company tra
Post# of 153933
(Total Views: 606)
Posted On: 02/01/2022 8:46:52 PM
"What public company could buy another company trading at 60 cents for 50 dollars?"
The easy answer is any company with $50 billion could spend $50 billion on a company like Cytodyn. Buyouts are based on current and future valuation rather than share price. If you knew everything you know about Leronlimab and someone at your company (let's say you work at Gilead) said "maybe we should buy Cytodyn for $50 billion" would you think them a fool or would that be a steal?
Here's a look at the largest pharmaceutical acquisitions. The numbers are adjusted for inflation.
1. Pfizer $174 billion
2. Glaxo $114 billion
3. BMS $96 billion
4. Sanofi $88 billion
5. Actavis $77 billion
6. Pfizer $82 billion
7. Pfizer $83 billion
8. Takeda $64 billion
9. Bayer $68 billion
10. Merck $57 billion
I'd accept an argument that you doubt Cytodyn's buyout would/could be a top 10 all-time buyout. But even then the market is littered with buyouts above $20 billion. There's no way it's worth less than the $21 billion IMMU received for an arguably inferior mTNBC drug that can't do the rest of what LL can.
The easy answer is any company with $50 billion could spend $50 billion on a company like Cytodyn. Buyouts are based on current and future valuation rather than share price. If you knew everything you know about Leronlimab and someone at your company (let's say you work at Gilead) said "maybe we should buy Cytodyn for $50 billion" would you think them a fool or would that be a steal?
Here's a look at the largest pharmaceutical acquisitions. The numbers are adjusted for inflation.
1. Pfizer $174 billion
2. Glaxo $114 billion
3. BMS $96 billion
4. Sanofi $88 billion
5. Actavis $77 billion
6. Pfizer $82 billion
7. Pfizer $83 billion
8. Takeda $64 billion
9. Bayer $68 billion
10. Merck $57 billion
I'd accept an argument that you doubt Cytodyn's buyout would/could be a top 10 all-time buyout. But even then the market is littered with buyouts above $20 billion. There's no way it's worth less than the $21 billion IMMU received for an arguably inferior mTNBC drug that can't do the rest of what LL can.
(20)
(0)